News
May 1, 2024
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the cGAS-STING pathway to address indications in inflammation, autoimmunity and oncology, announced the appointment of Thomas W. Dubensky, Jr., Ph.D., as president and chief executive officer and a member of the Board of Directors, effective immediately. Dr.Read More